Schonfeld Strategic Advisors LLC
Position in JANX — Janux Therapeutics, Inc.
CIK 1665241
NEW YORK, NY
Position in JANX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$616,872
+$445,360 QoQ
Shares Held
40,161
+225.5% QoQ
Ownership
0.066%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#89
of 198 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names. JANX ranks #82 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INBX |
Inhibrx Biosciences, Inc.
|
697,586 | $66,096,273 | |
| 2 | AGIO |
Agios Pharmaceuticals, Inc.
|
520,083 | $19,300,280 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
77,272 | $18,620,233 | |
| 4 | VRDN |
Viridian Therapeutics, Inc.\DE
|
793,508 | $14,576,741 | |
| 5 | MBX |
MBX Biosciences, Inc.
|
248,670 | $13,726,584 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
227,330 | $13,721,638 | |
| 7 | PTCT |
Ptc Therapeutics, Inc.
|
147,425 | $12,025,457 | |
| 8 | INSM |
INSMED Inc
|
104,378 | $11,128,782 |
All Filings in JANX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $616,872 | 40,161 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $171,512 | 12,339 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $627,251 | 45,453 | Shares | Sole | 2026-02-17 | |
| 2024-12-31 | $5,862,630 | 109,500 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $6,785,197 | 149,355 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $10,159,623 | 242,531 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $5,749,945 | 152,721 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||